questionsmedicales.fr
Cellules
Cellules épithéliales
Hépatocytes
Cellules HepG2
Cellules HepG2 : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
2
Carcinome hépatocellulaire
Lignées cellulaires
Culture cellulaire
Microscopie
Symptômes
2
Symptômes
Cellules in vitro
Marqueurs tumoraux
Enzymes hépatiques
Prévention
2
Prévention des maladies
Composés bioactifs
Recherche préventive
Toxines
Traitements
2
Essais cliniques
Toxicité
Développement de médicaments
Mécanismes d'action
Complications
2
Mécanismes pathologiques
Complications hépatiques
Facteurs de risque
2
Facteurs de risque
Toxines
Évaluation des risques
Agents toxiques
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Cellules HepG2 : Questions médicales les plus fréquentes",
"headline": "Cellules HepG2 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Cellules HepG2 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-11",
"dateModified": "2025-02-05",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Cellules HepG2"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Hépatocytes",
"url": "https://questionsmedicales.fr/mesh/D022781",
"about": {
"@type": "MedicalCondition",
"name": "Hépatocytes",
"code": {
"@type": "MedicalCode",
"code": "D022781",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "A11.436.348"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Cellules HepG2",
"alternateName": "Hep G2 Cells",
"code": {
"@type": "MedicalCode",
"code": "D056945",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Wilson de Melo Cruvinel",
"url": "https://questionsmedicales.fr/author/Wilson%20de%20Melo%20Cruvinel",
"affiliation": {
"@type": "Organization",
"name": "School of Medical and Life Sciences, Escola de Ciências Médicas e da Vida, Pontifícia Universidade Católica de Goiás (PUC GOIÁS), Avenida Universitária 1.440, Setor Universitário, Goiânia, GO, 74605-010, Brazil. melocruvinel@gmail.com."
}
},
{
"@type": "Person",
"name": "Paulo Luiz Carvalho Francescantonio",
"url": "https://questionsmedicales.fr/author/Paulo%20Luiz%20Carvalho%20Francescantonio",
"affiliation": {
"@type": "Organization",
"name": "School of Medical and Life Sciences, Escola de Ciências Médicas e da Vida, Pontifícia Universidade Católica de Goiás (PUC GOIÁS), Avenida Universitária 1.440, Setor Universitário, Goiânia, GO, 74605-010, Brazil."
}
},
{
"@type": "Person",
"name": "Alessandra Dellavance",
"url": "https://questionsmedicales.fr/author/Alessandra%20Dellavance",
"affiliation": {
"@type": "Organization",
"name": "Research and Development Division, Fleury Medicine and Health Laboratories, São Paulo, Brazil."
}
},
{
"@type": "Person",
"name": "Luis Eduardo Coelho Andrade",
"url": "https://questionsmedicales.fr/author/Luis%20Eduardo%20Coelho%20Andrade",
"affiliation": {
"@type": "Organization",
"name": "Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil. luis.andrade@unifesp.br."
}
},
{
"@type": "Person",
"name": "Antônio Carlos Ximenes",
"url": "https://questionsmedicales.fr/author/Ant%C3%B4nio%20Carlos%20Ximenes",
"affiliation": {
"@type": "Organization",
"name": "Hospital Geral de Goiânia Alberto Rassi, Goiânia, GO, Brazil."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Proton Pumps: Molecular Mechanisms, Inhibitors and Activators of Proton Pumping.",
"datePublished": "2023-05-22",
"url": "https://questionsmedicales.fr/article/37240416",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms24109070"
}
},
{
"@type": "ScholarlyArticle",
"name": "Partitioning of discrete proton arcs into interlaced subplans can bring proton arc advances to existing proton facilities.",
"datePublished": "2023-07-21",
"url": "https://questionsmedicales.fr/article/37482909",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/mp.16617"
}
},
{
"@type": "ScholarlyArticle",
"name": "Molecular magneto-ionic proton sensor in solid-state proton battery.",
"datePublished": "2022-11-17",
"url": "https://questionsmedicales.fr/article/36396649",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41467-022-34874-6"
}
},
{
"@type": "ScholarlyArticle",
"name": "Using Proton Geminate Recombination as a Probe of Proton Migration on Biological Membranes.",
"datePublished": "2022-08-03",
"url": "https://questionsmedicales.fr/article/35921517",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1021/acs.jpcb.2c00953"
}
},
{
"@type": "ScholarlyArticle",
"name": "Protonation of Homocitrate and the E",
"datePublished": "2023-11-21",
"url": "https://questionsmedicales.fr/article/37987624",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1021/acs.inorgchem.3c02329"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Cellules",
"item": "https://questionsmedicales.fr/mesh/D002477"
},
{
"@type": "ListItem",
"position": 3,
"name": "Cellules épithéliales",
"item": "https://questionsmedicales.fr/mesh/D004847"
},
{
"@type": "ListItem",
"position": 4,
"name": "Hépatocytes",
"item": "https://questionsmedicales.fr/mesh/D022781"
},
{
"@type": "ListItem",
"position": 5,
"name": "Cellules HepG2",
"item": "https://questionsmedicales.fr/mesh/D056945"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Cellules HepG2 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Cellules HepG2",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-01",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Cellules HepG2",
"description": "Comment identifier les cellules HepG2 en laboratoire ?\nQuelles techniques sont utilisées pour étudier les HepG2 ?",
"url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Protons#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Cellules HepG2",
"description": "Les cellules HepG2 présentent-elles des symptômes ?\nQuels marqueurs sont associés aux cellules HepG2 ?",
"url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Protons#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Cellules HepG2",
"description": "Les cellules HepG2 peuvent-elles aider à prévenir des maladies ?\nComment les HepG2 contribuent-elles à la recherche préventive ?",
"url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Protons#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Cellules HepG2",
"description": "Peut-on utiliser HepG2 pour tester des médicaments ?\nComment les HepG2 aident-elles à développer des traitements ?",
"url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Protons#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Cellules HepG2",
"description": "Quelles complications peuvent être étudiées avec HepG2 ?\nLes HepG2 aident-elles à comprendre les complications du foie ?",
"url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Protons#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Cellules HepG2",
"description": "Quels facteurs de risque sont étudiés avec HepG2 ?\nComment HepG2 aide à identifier des facteurs de risque ?",
"url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Protons#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier les cellules HepG2 en laboratoire ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les cellules HepG2 peuvent être identifiées par leur morphologie et leur marqueur spécifique, l'alpha-fœtoprotéine."
}
},
{
"@type": "Question",
"name": "Quelles techniques sont utilisées pour étudier les HepG2 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les techniques incluent la culture cellulaire, la microscopie et les tests de viabilité cellulaire."
}
},
{
"@type": "Question",
"name": "Les cellules HepG2 présentent-elles des symptômes ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les cellules HepG2 ne présentent pas de symptômes, car elles sont des cellules in vitro."
}
},
{
"@type": "Question",
"name": "Quels marqueurs sont associés aux cellules HepG2 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les cellules HepG2 expriment des marqueurs comme l'alpha-fœtoprotéine et des enzymes hépatiques."
}
},
{
"@type": "Question",
"name": "Les cellules HepG2 peuvent-elles aider à prévenir des maladies ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont utilisées pour étudier les effets préventifs de composés sur les maladies hépatiques."
}
},
{
"@type": "Question",
"name": "Comment les HepG2 contribuent-elles à la recherche préventive ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles permettent d'analyser les effets de l'alimentation et des toxines sur la santé hépatique."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser HepG2 pour tester des médicaments ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les cellules HepG2 sont souvent utilisées pour évaluer la toxicité et l'efficacité des médicaments."
}
},
{
"@type": "Question",
"name": "Comment les HepG2 aident-elles à développer des traitements ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles permettent d'étudier les mécanismes d'action des médicaments sur le foie et d'identifier des cibles thérapeutiques."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent être étudiées avec HepG2 ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications liées aux maladies hépatiques, comme la cirrhose et le cancer du foie, peuvent être modélisées."
}
},
{
"@type": "Question",
"name": "Les HepG2 aident-elles à comprendre les complications du foie ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles sont essentielles pour étudier les mécanismes des complications hépatiques."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont étudiés avec HepG2 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs de risque comme l'alcool, les médicaments et les toxines sont souvent analysés."
}
},
{
"@type": "Question",
"name": "Comment HepG2 aide à identifier des facteurs de risque ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles permettent d'évaluer l'impact de divers agents sur la santé des cellules hépatiques."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 05/02/2025
Contenu vérifié selon les dernières recommandations médicales
5 publications dans cette catégorie
Affiliations :
School of Medical and Life Sciences, Escola de Ciências Médicas e da Vida, Pontifícia Universidade Católica de Goiás (PUC GOIÁS), Avenida Universitária 1.440, Setor Universitário, Goiânia, GO, 74605-010, Brazil. melocruvinel@gmail.com.
Publications dans "Cellules HepG2" :
5 publications dans cette catégorie
Affiliations :
School of Medical and Life Sciences, Escola de Ciências Médicas e da Vida, Pontifícia Universidade Católica de Goiás (PUC GOIÁS), Avenida Universitária 1.440, Setor Universitário, Goiânia, GO, 74605-010, Brazil.
Publications dans "Cellules HepG2" :
4 publications dans cette catégorie
Affiliations :
Research and Development Division, Fleury Medicine and Health Laboratories, São Paulo, Brazil.
Publications dans "Cellules HepG2" :
4 publications dans cette catégorie
Affiliations :
Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil. luis.andrade@unifesp.br.
Immunology Division, Fleury Medicine and Health Laboratories, São Paulo, Brazil. luis.andrade@unifesp.br.
Publications dans "Cellules HepG2" :
3 publications dans cette catégorie
Affiliations :
Hospital Geral de Goiânia Alberto Rassi, Goiânia, GO, Brazil.
Publications dans "Cellules HepG2" :
3 publications dans cette catégorie
Affiliations :
Departamento de Patologia Clínica e Anatomia Patológica, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
Publications dans "Cellules HepG2" :
3 publications dans cette catégorie
Affiliations :
Faculdade de Medicina, Hospital das Clinicas HCFMUSP, Universidade de Sao Paulo, São Paulo, SP, Brazil.
Publications dans "Cellules HepG2" :
3 publications dans cette catégorie
Affiliations :
Department of Clinical Pathology, School of Medicine, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil.
Hermes Pardini Group, Vespasiano, MG, Brazil.
Publications dans "Cellules HepG2" :
3 publications dans cette catégorie
Affiliations :
Serviço de Reumatologia e Laboratório de Autoimunidade da Divisão de Laboratório Central do Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.
Publications dans "Cellules HepG2" :
3 publications dans cette catégorie
Affiliations :
Sociedade Brasileira de Autoimunidade, Porto Alegre, RS, Brazil.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
College of Life Science, Sichuan Agricultural University, Ya'an 625014, China.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
College of Life Science, Sichuan Agricultural University, Ya'an 625014, China.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
College of Life Science, Sichuan Agricultural University, Ya'an 625014, China.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
College of Life Science, Sichuan Agricultural University, Ya'an 625014, China.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
College of Life Science, Sichuan Agricultural University, Ya'an 625014, China.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
College of Life Science, Sichuan Agricultural University, Ya'an 625014, China.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
State Key Laboratory of Marine Resource Utilization in South China Sea, School of Materials Science and Engineering, Hainan University, Haikou 570228, China. Electronic address: liv880213@foxmail.com.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
Hainan Provincial Key Laboratory for Tropical Hydrobiology and Biotechnology, School of Marine Science, Hainan University, Haikou 570228, China. Electronic address: xiexi@hainu.edu.cn.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
State Key Laboratory of Marine Resource Utilization in South China Sea, School of Materials Science and Engineering, Hainan University, Haikou 570228, China. Electronic address: 1532892231@qq.com.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
State Key Laboratory of Marine Resource Utilization in South China Sea, School of Materials Science and Engineering, Hainan University, Haikou 570228, China. Electronic address: luolijie4567@163.com.
Publications dans "Cellules HepG2" :
Protein molecular machines, also known as proton pumps, are the most important element of biological membranes [...]....
Proton arcs have shown potential to reduce the dose to organs at risks (OARs) by delivering the protons from many different directions. While most previous studies have been focused on dynamic arcs (d...
To exploit the dosimetric advantages of proton arcs, while achieving reasonable delivery times, we propose a partitioning approach where discrete arc plans are split into subplans to be delivered over...
For three oropharyngeal cancer patients, four different arc plans have been created and compared to the corresponding clinical IMPT plan. The treatment plans are all planned to be delivered in 35 frac...
The delivery time (including an additional delay of 30 s between the discrete directions to simulate manual interaction with the treatment control system) is reduced from on average 25.2 min for the 1...
Discrete proton arcs can be implemented at any proton facility with reasonable treatment times using a partitioning approach. The technique also makes the proton arc treatments more robust to changes ...
High proton conductivity originated from its small size and the diffusion-free Grotthuss mechanism offers immense promise for proton-based magneto-ionic control of magnetic materials. Despite such pro...
Proton migration on biological membranes plays a major role in cellular respiration and photosynthesis, but it is not yet fully understood. Here we show that proton dissociation kinetics and related g...
Nitrogenase is the only enzyme that can cleave the strong triple bond in N...
The transmembrane-electrostatically localized protons (TELP) theory can serve as a unified framework to explain experimental observations and elucidate bioenergetic systems including both delocalized ...
Proton imaging makes use of high-energy, low-intensity proton beams that fully traverse the patient and has been suggested to reduce range uncertainty in proton therapy. Upright patient positioning wi...
The purpose of this work was to determine whether proton treatment and imaging with an upright patient positioning system on a fixed beamline were acceptable from a radiation shielding perspective. Th...
The Geant4 Monte Carlo toolkit was used for the radiation shielding assessment. The calculations consisted of the generation of secondary particle phase-space files by simulating the passage of high-e...
The total yields of pions from a 330-MeV proton beam were many orders of magnitude less than that of neutrons and photons. Three-dimensional maps of ambient dose rate for a 330-MeV proton beam showed ...
Pion production has a negligible impact on the radiation shielding of proton imaging at 330 MeV relative to neutron and photon production. Radiation shielding designed for proton therapy is adequate f...
In bacteriorhodopsin, representative light-driven proton pump, five proton transfers yield vectorial active proton translocation, resulting in a proton gradient in microbes. Third proton transfer occu...
Otopetrin (Otop) proteins were recently found to function as proton channels, with Otop1 revealed to be the sour taste receptor in mammals. Otop proteins contain twelve transmembrane segments (S1-S12)...
Complex I is a key proton-pumping enzyme in bacterial and mitochondrial respiratory electron transport chains. Using quantum chemistry and electrostatic calculations, we have examined the pKa of the r...